Bristol Myers Squibb Company $BMY Stock Position Reduced by R Squared Ltd

R Squared Ltd cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 53.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,745 shares of the biopharmaceutical company's stock after selling 25,147 shares during the period. R Squared Ltd's holdings in Bristol Myers Squibb were worth $1,173,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BMY. Man Group plc increased its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Two Sigma Investments LP increased its position in Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company's stock worth $245,946,000 after purchasing an additional 4,588,601 shares during the last quarter. Van ECK Associates Corp increased its position in Bristol Myers Squibb by 67.8% in the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company's stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Bristol Myers Squibb by 31.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company's stock worth $669,012,000 after purchasing an additional 3,522,696 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Bristol Myers Squibb by 56.0% in the 3rd quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company's stock worth $426,352,000 after purchasing an additional 3,396,041 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company's stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.05% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BMY has been the topic of several research reports. Citigroup upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "neutral" rating in a research report on Friday, February 6th. Cantor Fitzgerald upped their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 8th. UBS Group reaffirmed a "buy" rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Morgan Stanley reaffirmed an "underweight" rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Stock Performance

BMY opened at $57.86 on Tuesday. The firm has a market capitalization of $118.13 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The stock's 50 day moving average price is $59.63 and its two-hundred day moving average price is $54.31. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.